

## Densely Ionizing Radiation Acts via the Microenvironment to Promote Aggressive *Trp53* Null Mammary Carcinomas

Irineu Illa-Bochaca<sup>1</sup>, Haoxu Ouyang<sup>1</sup>, Jonathan Tang<sup>3</sup>, Christopher Sebastiano<sup>2</sup>, Jian-Hua Mao<sup>3</sup>,  
Sylvain V. Costes<sup>3</sup>, Sandra Demaria<sup>1,2</sup> and Mary Helen Barcellos-Hoff<sup>1,4</sup>

<sup>1</sup> Department of Radiation Oncology, New York University School of Medicine, 566 First Avenue,  
New York, NY 10016, USA

<sup>2</sup> Department of Pathology, New York University School of Medicine, 566 First Avenue, New York,  
NY 10016, USA

<sup>3</sup> Life Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, MS977, Berkeley  
CA 94720, USA

#### <sup>4</sup> Address reprint requests to

Mary Helen Barcellos-Hoff

Department of Radiation Oncology

New York University, School of Medicine

566 First Avenue, New York, NY 10016

Phone: 212-263-3021

E-mail: [mhbarcellos-hoff@nyumc.org](mailto:mhbarcellos-hoff@nyumc.org)

**Running Title:** Microenvironment Mediated *Trp53* Null Carcinogenesis

#### **Author Contributions:**

Irineu Illa-Bochaca: Collection and/or assembly of data; Data analysis and interpretation;  
Manuscript preparation

Haoxu Ouyang: Data analysis and interpretation, manuscript preparation

Jonathan Tang; Collection and/or assembly of data; Data analysis and interpretation; Manuscript  
preparation

Christopher Sebastiano: Collection and/or assembly of data; Data analysis and interpretation

Jian-Hua Mao: Collection and/or assembly of data; Data analysis and interpretation; Manuscript writing

Sandra Demaria: Data analysis and interpretation; Manuscript writing

Mary Helen Barcellos-Hoff: Conception and design; Financial support; Collection and/or assembly of data; Data analysis and interpretation; Manuscript writing; Final approval of manuscript

**Corresponding Author:**

Mary Helen Barcellos-Hoff

Department of Radiation Oncology

New York University, School of Medicine

566 First Avenue, New York, NY 10016

Phone: 212-263-3021

E-mail: [mhbarcellos-hoff@nyumc.org](mailto:mhbarcellos-hoff@nyumc.org)

**Words:** 7806

**Figures:** 6

**Supplemental Figures:** 5

**Conflict of Interest:** The authors have no conflicts of interest regarding the data reported herein.

**Funding Acknowledgment:** This research was supported by NASA Specialized Center for Research in Radiation Health Effects, NNX09AM52G.

**Key Words:** ionizing radiation; breast cancer; HZE; promotion; carcinogenesis; cancer subtypes

## ABSTRACT

Densely ionizing radiation, which is present in the space radiation environment and used in radiation oncology, has potentially greater carcinogenic effect compared to sparsely ionizing radiation that is prevalent on earth. Here we used a radiation chimera in which mice were exposed to densely ionizing 350 MeV/amu Si-particles,  $\gamma$ -radiation, or sham-irradiated and transplanted 3 days later with syngeneic *Trp53* null mammary fragments. *Trp53* null tumors arising in mice densely irradiated had a shorter median time to appearance and grew faster once detected compared to those in sham-irradiated or  $\gamma$ -irradiated mice. Tumors were further classified by markers keratin 8/18 (K18, *KRT18*), keratin 14 (K14, *KRT18*) and estrogen receptor (ER, *ESR1*) and expression profiling. Most tumors arising in sham irradiated hosts were comprised of both K18 and K14 positive cells (K14/18) while those tumor arising in irradiated hosts were mostly K18. Keratin staining was significantly associated with ER status. K14/18 tumors were predominantly ER positive while K18 tumors were predominantly ER negative. Genes differentially expressed in K18 tumors compared to K14/18 tumor were associated with ERBB2 and KRAS, metastasis and loss of E-cadherin. Although K18 tumors tended to grow faster and be more metastatic than K14/18 tumors, K18 tumors in particle-irradiated mice grew significantly larger compared to controls and were more metastatic compared to sham-irradiated mice. An expression profile that distinguished K18 tumors arising in particle-irradiated compared sham-irradiated mice was enriched in mammary stem cell, stroma, and Notch signaling genes. These data suggest that the carcinogenic effects of densely ionizing radiation is mediated by the microenvironment, which elicits more aggressive tumors compared to similar tumors arising in sham-irradiated hosts.

## INTRODUCTION

Ionizing radiation is one of a few demonstrable carcinogens of the human breast (1). Sparsely ionizing radiation is prevalent in the terrestrial environment as well as in medical uses. Densely ionizing radiation is a major component of the space radiation environment and is gaining traction for use in radiation oncology. Both radiation types evoke acute and persistent, short and long range effects (2-5), but experimental data from mouse models suggest that densely ionizing radiation has potentially greater carcinogenic effects compared to sparsely ionizing radiation (6, 7). Microscopic dose distribution is a major difference between sparsely and densely ionizing radiation (7). Densely ionizing radiation from charged particles delivers a high dose to a very small volume along the trajectory of the particle while sparsely ionizing radiation delivers an equivalent dose throughout the volume. One may compare similar absorbed dose but microscopic distribution is different and the biological outcomes can be both quantitatively (e.g. cell kill, mutations) and qualitatively (e.g. gene expression, cell fate) different. Thorough understanding of the carcinogenic potential of densely ionizing radiation is important to assess the risk of space exploration and secondary malignant neoplasms following charged particle radiotherapy (8).

While DNA damage, misrepair and mutations are thought to underlie the increase in cancer following radiation exposure, we and others have postulated that altered signaling between irradiated cells and tissues also contribute to its carcinogenic potential (9, 10). We have shown that both sparsely and densely ionizing radiation affects epithelial phenotype, including epithelial to mesenchymal transition, stromal remodeling, stem/progenitor self-renewal, and genomic instability in human cells and mouse tissues (reviewed in (11, 12)). Many studies using oncogenic mouse models indicate that the stroma is highly involved in early malignancy (13) and that stroma composition and signaling is altered in human breast cancer (14), which support the idea of reciprocal evolution of the malignant cell and the tumor microenvironment (15). Less is known about how and when stroma contributes to carcinogenesis and how carcinogens like radiation might alter these processes.

Also unknown is to what extent the carcinogenic potential as a function of radiation quality is mediated by differential effects on the irradiated microenvironment. To address this issue, we developed a radiation chimera mammary model to separate radiation-induced microenvironment from radiation-induced mammary epithelial DNA damage and potential mutation (16). The mammary gland is surgically cleared of endogenous epithelium, the mouse is irradiated and the mammary fat pad subsequently orthotopically transplanted with un-irradiated, non-malignant epithelial cells that are primed for malignant transformation by *Trp53* deletion.

The *Trp53* null mammary chimera is widely used as a syngeneic mouse model for breast carcinogenesis (17-21). Outgrowths from *Trp53* null mammary epithelial transplants undergo broadly normal morphogenesis over the first 6 months and have a high rate of sporadic transformation and a slow rate of tumor formation. *Trp53* null mammary epithelium progresses from ductal outgrowths to ductal carcinoma *in situ* to invasive breast carcinomas over the course of a year or more. The resulting cancers are diverse, similar to human tumors, including genomic instability, differential expression of estrogen receptor  $\alpha$  (ER) and heterogeneous histology (19, 20, 22). This model has been used successfully to evaluate hormonal prevention strategies (23, 24), test chemopreventive agents (25-27), demonstrate the existence of cancer stem cells in mammary tumors (28, 29) and in our case study the mechanisms of ionizing radiation carcinogenesis.

In the radiation chimera model, in which mice are first irradiated prior to transplantation of *Trp53* null tissue, the incidence of tumors arising in mice irradiated with 10-100 cGy of sparsely ionizing radiation increased compared to sham-irradiated mice (30). Moreover, tumors in irradiated mice also grow more rapidly and exhibit a distinct molecular signature. Notably, the molecular signature of tumors arising in irradiated mice compared those arising in control mice is informative in human cancer. A host irradiation metaprofile consisting of 353 genes and modules representing stem cells, cell motility, macrophages and autophagy discriminates between tumors arising in sham- versus irradiated hosts (31). Human gene orthologs of this murine signature separates cancers arising in previously irradiated patients from sporadic cancers, which suggests that the carcinogenic effect of radiation mediated by the microenvironment is relevant to cancer risk in humans. When applied to sporadic human breast cancers, the irradiated host profile also clusters tumors according to

intrinsic molecular subtype, is associated strongly with basal-like tumors and specifically implicates TGF $\beta$ , a major signal in irradiated tissue, with immune and inflammatory modules in claudin-low human breast tumors. These bioinformatic analyses lend weight to the utility of the radiation chimera to provide new insight into both radiation-preceded and sporadic carcinogenic processes in humans.

The radiation-genetic chimera model demonstrates that radiation acts systemically on the host and tissue level to perpetuate and/or promote carcinogenic potential. Here we used the radiation mammary chimera model to evaluate the effect of densely ionizing radiation. The biological behavior and features of contemporaneous tumors arising from unirradiated *Trp53* null mammary epithelium transplanted to sham-irradiated mice were compared to tumors arising in mice irradiated with 3 fluences of 350 MeV/amu Si particles (LET=64 KeV/ $\mu$ m) or a reference dose of 100 cGy sparsely ionizing  $\gamma$ -radiation. Tumors arising in mice exposed to densely ionizing radiation grew significantly faster, were more likely to metastasize and could be genomically separated from tumors with the same markers arising in sham-irradiated mice. These data suggest that the carcinogenic effects of densely ionizing radiation mediated by the microenvironment is more effective in eliciting aggressive tumors.

## **MATERIALS AND METHODS**

*Animals.* All animal experiments were performed at New York University School of Medicine with institutional review and approval. BALB/c mice were purchased from Jackson Laboratory (Bar Harbor, Maine USA) and housed four per cage, fed with Lab Diet 5008 chow and water *ad libidum*. *Trp53* null BALB/c mice were bred in-house under similar conditions. For transplantation experiments, the epithelial rudiments in inguinal glands of 3 week old wildtype mice were surgically removed at NYU. The mice were housed at NYU until they were transported to Brookhaven National Laboratory at 8-9 weeks of age. After acclimation, groups of mice were whole body irradiated with institutional approval at 10 weeks of age with 100 cGy  $\gamma$ -radiation using a 5600 curie (207 TBq)  $^{137}\text{Cs}$  source or exposed to 3 fluences of 350 MeV/amu Si ions (64 KeV/ $\mu$ m) equivalent to 1, 3, or 5 particles/10  $\mu\text{m}^2$  (average dose 11, 30 and 81 cGy) delivered at the NASA Space Radiation

Laboratory of Brookhaven National Laboratory. Doses were chosen in accordance with NASA investigational guidance for relevance to space radiation environment. All cohorts were contemporaneous. Three days after irradiation, the cleared mammary glands of host mice were transplanted with  $\sim 1 \text{ mm}^3$  fragment of non-irradiated *Trp53* null mammary gland tissue that had been rapidly thawed from cryogenically preserved fragments of inguinal glands pooled from 3 or more, 8-10 week old *Trp53* null BALB/c donor mice.

Mice were quarantined for 6 weeks upon return to NYU and thereafter monitored by palpation 2-3 times per week for 600 days. Once a palpable tumor was detected, it was measured twice weekly using calipers until reaching  $1 \text{ cm}^3$ , at which point the first tumor was resected using survival surgery. Tumors were divided and frozen in liquid nitrogen for RNA extraction, embedded in OCT, or formalin fixed followed by paraffin embedding. The mouse was further observed until the resected tumor recurred, at which point the mouse was euthanized, or until the contralateral fat pad developed a tumor, which was monitored as above. A gross necroscopy was performed upon termination. If no tumor developed by experiment termination, then an inguinal gland wholemount was prepared to determine successful transplantation; mammary glands in which transplantation failed were censored. An informative transplant was defined as that which had an epithelial outgrowth evident by tumor development or confirmation at sacrifice at experiment termination.

*Immunohistochemistry.* Sections were deparaffinized and rehydrated prior to antigen unmasking according to manufacturer's instructions (Vector Labs, #H-3300), washed once with phosphate buffer saline and blocked with 0.5% casein/PBS for 1 hr at room temperature. Primary antibody for ER (NCL-ER-6F11, Novocastra), CK8/18 (20R-CP004, Fitzgerald), and K14 (PRB-155P, Covance) were diluted in Superblock Blocking Buffer (Pierce, #37515) and refrigerated overnight. The slides were washed, followed by incubation with fluorochrome-conjugated secondary antibody, washed and counterstained with 4',6-diamidino-2-phenylindole (DAPI) ( $2 \mu\text{g/ml}$ ; Molecular Probes). The Allred scoring system was used to determine ER status of tumors (32). Staining was technically confirmed by simultaneous inclusion of a positive control of normal mammary gland. Histopathological characteristics of the tumors were reviewed by two observers blinded to the experimental details

of the mouse models. Mitotic rate was counted in 5 high power field (HPF) for each tumor. Tumors were classified by two pathologists (CS and DM).

*Expression Profiling.* For tumors, total RNA quality and quantity was determined using Agilent 2100 Bioanalyzer and Nanodrop ND-1000. Affymetrix mouse Genechip 1.0 ST arrays were used according to manufacturer's protocol (GSE56704). Background subtraction and normalization was performed using the Robust Multichip Average algorithm from the Bioconductor package oligo (33). No filter was used unless specified as a SD of 1.0 relative to the expression values of that gene across all samples. Differentially regulated gene lists for pathway analysis were identified by feature selection algorithm Pavlidis template matching (PTM) (34) and using a p-value <0.05 and a 1.5 or 1.25 fold change criteria. Gene clustering was done by a Pearson correlation and array clustering was done by Spearman Rank correlation. Enriched gene sets or pathway and upstream regulators were identified through the use of ConceptGen, Gene Set Enrichment Analysis with MSigDB database v4.0 or IPA (Ingenuity<sup>®</sup>Systems).

*Statistical Analysis.* Statistical analysis of experimental data was performed using Prism (GraphPad). Differences between treatment groups were determined using the Chi-square test, Mann-Whitney test or two-way ANOVA, as indicated in text. Time to tumor occurrence was plotted using Kaplan-Meier with significance determined by the log-rank test. Tumor growth rates for the first 30 days post-palpation were fitted to an exponential curve, which were averaged for a treatment group. Differences were considered statistically significant at p<0.05. Multidimensional scaling analysis and discriminant analysis was done in SPSS (SPSS, Inc., Chicago, Illinois, USA).

## RESULTS

### ***Trp53* null mammary tumors develop more rapidly in mice exposed to densely ionizing radiation**

The experimental sequence for this study is shown in Fig. 1A. Ten week old mice were irradiated with either 100 cGy of  $\gamma$ -radiation or with 350 MeV/amu Si particles to an average dose 11, 30 or 81 cGy, which represent particle fluences of respectively 1, 3, or 8 particles per 10  $\mu\text{m}^2$ . Of 156 transplanted fat pads, 131 generated an outgrowth (84% transplant efficiency), and of these, 81 (62%)



generated a palpable tumor during the observation period of 600 days. The earliest tumors appeared around 200 days after transplantation. Tumor incidence at 600 days post transplantation (approximately 670 days of age) at experiment termination for sham,  $\gamma$ -irradiated and all Si-particle doses combined was 63% , 54%, 66%, respectively. No significant difference in transplantation efficiency or mortality was observed for irradiated groups compared to sham.

The median time to tumor detection in mice irradiated with the lowest Si-fluence or  $\gamma$ -radiation was similar to that in sham-irradiated mice but decreased in a dose dependent fashion for transplants in mice exposed to Si-irradiation. (Fig. 1B). Once palpable, the growth rate of individual *Trp53* null tumors was highly variable (Fig. 1C-G). To permit comparison among groups, each growth curve within a treatment group was fitted as an exponential curve, which was used to extrapolate tumor size for a period representing the 30 day post-detection. The r-values ( $>0.9$ ) indicate that this is a reliable representation of the growth trajectory, therefore, tumor sizes for all tumors in a treatment group were averaged for every day of the 30 days independent of when the tumor arose. The growth rate of tumors arising in irradiated mice was increased compared to those arising in sham-irradiated mice (Supplemental Fig. S1). The initial growth rate (i.e. first 30 days) of tumors arising in mice exposed to 81 cGy and 30 cGy Si-particles was significantly faster than tumors in sham-irradiated mice (Fig. 1H). The initial growth rate of tumors arising in hosts irradiated with 11 cGy Si-particles was comparable to that of tumors arising in mice irradiated with 100 cGy sparsely ionizing  $\gamma$ -rays, which showed modestly increased growth compared to tumors in sham-irradiated hosts, as was previously reported (30). The effect of host irradiation with either 100 cGy  $\gamma$  or 11 cGy Si-particles ( $\sim 1$  particle/cell) on decreased median latency and increased tumor growth rate were comparable, indicating an relative biological effectiveness of 10.

*Trp53* tumors are histologically and molecularly diverse (19, 20, 22). The features of tumors as function of host irradiation are summarized in Supplemental Table S1. Most tumors were adenocarcinomas and the remaining were metaplastic carcinomas. The distribution of tumor

histology was not affected by host irradiation, except in the high dose Si-particle irradiated mice, in which there were more metaplastic carcinomas.

Approximately 70% of human breast cancers are positive for ER by immunostaining, which is a positive prognostic factor whereas the prognosis for ER-negative breast cancer is much poorer (35). Our prior studies showed that hosts irradiated with either sparsely or densely ionizing radiation shifted the dominant tumor type from ER positive to ER negative (30, 36). Most (62%, n=15/24) tumors arising in sham-irradiated mice were ER positive, compared to 33% (n=4/12) in  $\gamma$ -irradiated hosts and 43% (n=15/35) in Si-irradiated (combined dose groups) hosts. Given this differential, we asked whether growth rate changed as a function of ER status. There was little difference between the growth rate ER-negative tumors and ER-positive tumors (Supplemental Fig. S2), which does not support ER status as a primary determinant of growth rate. However, ER-negative tumors arising in Si-particle irradiated hosts grew significantly faster than those in either sparsely ionizing irradiated or sham-irradiated hosts. The gain in tumor volume in the initial 30 days for ER-negative tumors arising in Si-particle irradiated hosts was more than 4-times ( $1033 \pm 541 \text{ mm}^3$ , n=20) that of tumors in sham-irradiated hosts ( $171 \pm 95 \text{ mm}^3$ , n=9) or  $\gamma$ -irradiated hosts ( $150 \pm 80 \text{ mm}^3$ , n=8), suggesting that host particle irradiation promotes more aggressive tumors, as well as increasing the prevalence of ER-negative tumors.

Tumor type is thought to be related to the cell of origin (reviewed in (37)). The murine mammary gland consists of two major cell types, basal myoepithelial cells that express keratin 14 (K14) and p63, and luminal cells that express keratin 8/18 (K18) and steroid hormone receptors, similar to those found in human breast (38). Dual immunofluorescence for K14 and K18 demonstrates these distinct cell types in normal mouse mammary epithelium (Fig. 2A). We then classified tumors using dual K14/K18 immunostaining. Five patterns of keratin reactivity were identified in tumors (Fig. 2B-F): predominantly (>80%) K14, predominantly K18, tumors composed of both K14 and K18 cells organized in a pseudoglandular pattern (designated K14/18), tumors in which at least 30% of cells were positive for both keratins simultaneously, and tumors negative for either.

The distribution of tumor keratin patterns was significantly different between hosts irradiated with sparsely (n=12) or densely (n=35) ionizing radiation compared to tumors arising in sham irradiated hosts (n=24; Fig. 2G-J). Most tumors that arose in sham-irradiated hosts were K14/18, whereas host irradiation with either radiation quality favored K18 tumors at the expense of K14/18 tumors (chi-square,  $p < 0.05$ ).

Keratin staining was significantly associated with ER status (chi-square,  $p < 0.001$ ). K14/18 tumors were predominantly ER positive (16/20, 80%) and K18 tumors were predominantly ER negative (17/22, 77%) (Fig. 2K). Interestingly tumors that were negative for either keratin were frequently ER negative and were absent from  $\gamma$ -irradiated mice and were more frequent in Si-irradiated hosts compared to sham-irradiated hosts (Fig. 2L-N). These data suggest that host Si-irradiation primarily promotes specific ER-negative subtypes.

Although K18 tumors tended to grow faster than K14/18 tumors, host irradiation with either radiation type significantly increased K18 tumor initial growth but Si-particle host irradiation was significantly more effective than  $\gamma$ -radiation (Fig. 3A). However, K14/18 tumor growth was not increased in irradiated hosts compared to the sham-irradiated hosts (Fig. 3B). In support of a distinct biology of K18 tumors in irradiated hosts, the metastatic potential of K18 tumors was increased in irradiated hosts (Fig. 3C) but this was not observed in mice with K14/18 tumors (Fig. 3D). These data suggested that host irradiation both enriches for a particular tumor type and promotes its progression.

Given the complexity of tumor features, we then conducted multi-dimensional scaling analysis to determine which phenotypes associate with each other. Tumors arising in 11 cGy Si-particle or 100 cGy  $\gamma$ -irradiated hosts were grouped close together with those arising in sham-irradiated mice based on ER status, lung tumor, necrosis and invasion, which was only weakly associated with keratin status (Fig. 4A). Latency, growth rate and mitotic index were independent of this cluster and with each other. For tumors arising in mice irradiated with 30 or 81 cGy Si particles, nuclear grade was grouped with ER status, lung tumor, necrosis and invasion, and again weakly associated with keratin type (Fig. 4B). However, consistent with their increased growth rate, mitotic rate and

tumor growth rate were associated with each other in this group. Interestingly, latency was not associated with any feature in any group. Discriminant analysis also indicated that tumors arising in 11 cGy Si, 100 cGy and sham-irradiated hosts were more similar than those arising 30 and 81 cGy Si-particle irradiated hosts (Fig. 4C).

### **Expression signatures of tumors arising in Si-particle irradiated hosts.**

Given the shift in tumor subtype elicited in the context of the Si-particle irradiated host, we used Affymetrix mouse Genechip 1.0 ST arrays to profile 45 tumors and conducted unsupervised hierarchical clustering of genes with variability greater than 1 standard deviation across samples. We noted that almost all K14/18 (11/14) and K18 (11/12) tumors were clustered in one of two major dendrogram arms (Supplemental Fig. S3). We then compared the profiles of these keratin subtype tumors arising in sham-irradiated mice. PTM identified 330 up-regulated genes and 367 down-regulated genes in K18 compared to K14/18 tumors (Fig. 5A). The human orthologs of these gene lists (278/330 and 295/367) were classified using ConceptGen and gene set enrichment analysis (GSEA). Among those genes decreased in K18 compared to K14/18 tumors are significantly enriched of genes suppressed in metastasis lesion ( $p=1.20 \times 10^{-35}$ ) or by loss of E-cadherin ( $p=1.25 \times 10^{-24}$ ). In terms of function, those genes, such as *Col17a1*, *Lama3*, and *Cdh3*, have been shown to be involved in cell adhesion and cell-cell junction (Fig. 5A). Consistent with this, the frequency of lung metastasis was increased in mice bearing K18 tumors compared to K14/18 tumors (Fig. 3 C, D).

The K18 tumor profile was also enriched in genes that are present in the luminal B breast cancer signature ( $p=0.005$ ) while genes highly expressed in basal breast cancer were under expressed ( $p=6.70 \times 10^{-4}$ ). Classic basal keratins Krt5 and Krt14 were under expressed in K18 tumors. Genes represented in the MaSC signature, defined by Lim and colleagues (39), were enriched in both tumors but, interestingly, their expression was in the opposite direction; that is, genes highly expressed in MaSC were suppressed in K18 tumors (Supplemental Fig. S4). Genes increased in K18 tumors were enriched in genes up regulated with activation of ERBB2 ( $p=2.56 \times 10^{-36}$ ) and KRAS ( $p=5.46 \times 10^{-12}$ ). Activation of these genes is strongly associated with aggressive tumors (28, 29). Moreover, several components of Wnt signaling were overexpressed in K18 tumors (Fig. 5A), which

may contribute to the aggressiveness of K18 tumors. Consistent with all these molecular features, tumor growth rate of K18 tumors in sham-irradiated mice tended to grow slightly faster than K14/18 tumors but this was not significantly different, possibly due to the small numbers of tumors in sham-irradiated mice.

Together these data suggested that K18 and K14/18 tumors may be murine correlates of basal-like and luminal human tumors respectively. To test this idea, we evaluated how the biology represented by the K18 vs K14/18 profile relates to human breast cancer. We used a database that consists of 1608 breast cancers classified using PAM50 into 5 intrinsic subtypes (40). The human orthologs of the K18 vs K14/18 profile clustered breast cancer into two major groups (Fig. 5B). One group contained many normal-like tumors and luminal tumors but almost no basal-like tumors. The other major group has three subgroups. Group 2A mainly consists of basal-like and normal-like tumors while group 2B is filled with basal-like tumor predominately. Group 2C contains a block of luminal tumors and two blocks of mixed tumors. Thus the biology of *Trp53* null tumors with specific keratin markers has discriminant power in classifying human breast cancer.

We also conducted a similar PTM analysis ( $p < 0.05$ ,  $FC > 1.25$ ) of tumors arising in Si-irradiated hosts compared to sham-irradiated hosts as a function of ER status (Fig. 5 C,D). Host irradiation exerts more robust effects on gene expression profile in ER-negative than ER-positive tumors in that 1078 genes were differentially expressed in ER-negative tumors while only 154 genes were ER-positive tumors. The MaSC signature was highly enriched in ER-negative tumors arising in irradiated hosts ( $p = 1.6 \times 10^{-4}$ ) but not in ER-positive tumors ( $p = 3.2 \times 10^{-1}$ ).

### **Expression profiles of tumors arising in Si particle irradiated hosts**

Given the more aggressive behavior of K18 tumors in Si-irradiated hosts we hypothesized that they would be genomically distinct. To explore the effect of host irradiation on specific tumor types, we used PTM to generate Si-irradiated host profiles for K18 tumors (K18-IHPsi) and K14/18 tumors (K14/18-IHPsi). We were unable to make a comparison to similar tumors from  $\gamma$ -irradiated hosts because of the small number of contemporaneous tumors. We used PTM to identify 295 up-

regulated genes (corresponding to 241 human orthologs) and 162 down-regulated genes (corresponding to 111 human orthologs) in K18 tumors arising in Si-irradiated host compared to tumors arising in sham-irradiated. In contrast, gene expression profiles of K14/18 tumors arising in Si-irradiated hosts were more similar to those arising in sham-irradiated mice. Only 160 genes were differentially regulated: 106 up-regulated genes (corresponding to 94 human orthologs) and 54 down-regulated genes (corresponding to 46 human orthologs). Only 9 genes were common between K18-IHPsi and K14/18-IHPsi, suggesting that host irradiation affected each tumor type differently.

IPA analysis revealed that different networks were affected by host irradiation in each tumor type. Cell cycle pathways including estrogen-mediated S-phase entry and G1/S checkpoint regulation were enriched in K18-IHPsi (Fig. 6A). Expression of *CCND1*, *E2F3* and *E2F4* were elevated by 65%, 70%, and 90% respectively in K18 tumors arising from Si-irradiated hosts compared to sham-irradiated hosts, consistent with their significantly faster growth rate. Epithelial-mesenchymal transition pathways were significantly associated with K18-IHPsi (Fig. 6A). Predictive analysis of the upstream regulators in K18-IHPsi signature include genes implicated in pro-inflammatory immune response (*TNF*, *IL4* and *IL6*), TGF $\beta$  pathway members and targets important for microenvironment and angiogenesis (*TGM2*, *FGF2*, *SMAD3*, *TGF $\beta$ 1*, *VEGFA*), and well-known genes in the canonical oncogenic signaling (*EGF*, *ERBB2*, *AKT1*, *ERK1/2*) (Fig. 6B). Notably, none of these pathways or upstream regulators was activated in K14/18-IHPsi (Fig. 6A-B).

Aberrant Notch activation is associated with poor outcomes in human breast cancer, possibly via its role in regulating MaSC and luminal progenitor cells (41, 42). As found previously in irradiated tissues and tumors arising in  $\gamma$ -irradiated mice (30, 31), Notch signaling was activated in K18-IHPsi (Fig. 6A). In addition, both ConceptGen analysis and GSEA of K18-IHPsi found enrichment of genes highly expressed in the MaSC ( $p=2.33\times 10^{-7}$ ) and stroma cell signatures ( $p=1.33\times 10^{-7}$ ) defined by Lim and colleagues (33). Genes decreased in MaSC signature were also decreased in K18-IHPsi ( $p=7\times 10^{-5}$ ), consistent with their ER-negative status, and likely reflecting the MaSC as cell of origin [Tang, 2013]. This signature was not evident in K14/18-IHPsi, suggesting that host irradiation has tumor-specific engagement (Supplemental Fig. S5). Together these data demonstrate that though *Trp53* tumors

classified by ER and keratin protein expression are genomically distinct, K18-positive, ER-negative tumors that arise in mice irradiated with Si particles are distinct from similar tumors that arose in sham-irradiated mice.

## Discussion

Here we show that densely ionizing radiation acts through the microenvironment to promote more aggressive behavior and characteristics of *Trp53* null mammary carcinomas. The galactic cosmic radiation environment is unlike any on earth because it includes charged particle species from protons through uranium at varying energies of up to tens of GeV/amu (7). Estimating the cancer risk of densely ionizing radiation for humans is difficult in the absence of exposed populations comparable to those exposed to sparsely ionizing radiation by accidents, medical need and atomic bomb detonation. The limited experimental data to date indicate that densely ionizing particles are more effective in inducing cancer than sparsely ionizing radiation. The unique pattern of energy deposition incurred by particle traversal is considered to be the basis for differences in the biological effects of the galactic cosmic radiation on astronauts (6). Comparison of sparsely and densely ionizing radiation indicates that greater relative biological effectiveness of densely ionizing radiation for many biological end points. However, some biological effects are not observed following sparsely ionizing radiation (43) and some radiation effects, like genomic instability, do not show classic dose responses (44).

Comparison of tumors arising in contemporaneous hosts that were  $\gamma$ -irradiated (100 cGy) to tumors arising in mice exposed to graded fluences of Si-particles suggest that densely ionizing radiation had greater biological effectiveness for two endpoints: median time to tumor and growth rate. Both accelerating tumor appearance and increasing growth rate also show some Si-particle fluence dependence, though it is difficult to estimate the magnitude without more complete dose response data. The effect of host irradiation with either 100 cGy  $\gamma$  or 11 cGy Si-particles ( $\sim 1$  particle/cell) on decreased median latency and increased tumor growth rate were comparable, indicating an relative biological effectiveness of 10. These data may be further complicated by interaction of factors, as

evident in the greater acceleration of ER-negative tumors arising in Si-particle irradiated hosts compared to  $\gamma$ -irradiated (Fig. S2).

We then attempted to determine whether distinct tumor types underlie the increased growth rate of tumors arising in Si-particle irradiated hosts using marker classification. Addition of basal and luminal cell keratins revealed a complex pattern of K18 and K14 expression. Notably, most ER-negative tumors were K18 positive and were increased in irradiated hosts. Unsupervised clustering of expression profiling suggested that keratin status was differentially distributed between the two major dendrogram arms. Direct comparison of K18 versus K14/18 tumors demonstrated that they are genomically distinct. The expression profile that distinguished the K18 from K14/18 was enriched in genes lost when E-cadherin is down regulated and decreased in metastatic tumors. Consistent with these programs, mice with K18 tumors were more likely to have lung metastases than K14/18 tumors. K18 tumor growth rate was not significantly greater than that of K14/18 tumors in sham-irradiated mice, but K18 tumor growth rate was significantly increased in irradiated hosts while that of K14/18 tumors was not. Thus, we concluded that tumors arising in Si-irradiated mice are enriched in ER-negative, K18-positive tumors that are intrinsically classified as more aggressive than ER-positive tumors, but there is an additional effect from the irradiated host that specifically affects these behaviors.

Cell type-based ontological and high-throughput molecular -omics are complimentary approaches to characterizing cancers (38). In a previous study, we found that gene expression profiles from  $\gamma$ - or Si-irradiated mammary gland tissue were comparable in terms of enriching for MaSC signature and implicating NOTCH, TGF $\beta$ , WNT pathways as upstream regulators (23) up to 12 weeks post-irradiation. Tumors arising in hosts irradiated with low doses of sparsely ionizing radiation show a distinct gene expression profile, even though tumors occur many months post-irradiation, and even when segregated by ER status (30, 31). Due to insufficient number of contemporaneous tumors from  $\gamma$ -irradiated host, we were not able to compare the quality difference at the molecular level as well as control for tumor markers. However, we compared the IHPsi (all doses) with our published 323 gene signature (323-IHC) derived from tumors arising in hosts exposed to sparsely ionizing radiation (31). Although stem cell signaling was invoked in both 323-IHC and IHPsi, there is no



overlap between the 323-IHC gene list and IHPsi, suggestive of a potential quality effect. In contrast, both K18-IHPsi and 323-IHC gene lists are enriched in TGF $\beta$  pathway, Notch signaling and MaSC signatures. Again, the genes in each pathway do not overlap between the K18-IHPsi and 323-IHC lists. It may be that the different platforms used in these studies compromises the comparison; future studies will need to either use the same platforms or convert data between platforms.

Determining the relative carcinogenic contribution of radiation targeted effects (e.g. genetic sequence) versus non-targeted effects (e.g. cell signaling) is important to understanding cancer susceptibility. Radiation induced DNA damage is broadly considered to be the primary mechanism determining its carcinogenic potential (45). There has been little change in this view of the biology underlying cancer risk in irradiated populations despite growing evidence that radiation affects systemic and cellular signaling in a complex and persistent fashion (9, 10, 46, 47). One of the main differences between these targeted and non-targeted response is the shape of the dose response. Signaling-mediated biology often shows switch-like dose dependence, as is seen in cells primed by radiation to undergo epithelial-mesenchymal transition (48). The tendency toward a saturation dose response would likely be more evident with more comprehensive dose/fluence response data for both densely and sparsely ionizing radiation.

Together, the data from this study support the idea that response of the host and microenvironment to radiation exposure significantly contribute to the carcinogenic process. Some endpoints (i.e. median latency, growth rate) suggest that densely ionizing radiation is more effective than sparsely ionizing radiation in stimulating progression. This possibility is more likely to be of immediate concern for predicting risk of second neoplasms following charged particle radiotherapy (8). Given that densely ionizing radiation acts through the microenvironment to increase tumor aggressiveness, it will be important to incorporate host determinants of cancer into risk modeling of radiation exposures in space and on earth.

## Acknowledgements

The authors would like to acknowledge expert assistance from William Chou and Derek Francis. Funding was provided by National Aeronautics and Space Administration Specialized Center for Research in Radiation Health Effects NNX09AM52G at New York University School of Medicine.



## References

1. Land CE, Boice JD, Shore RE, Norman JE, Tokunaga M. Breast cancer risk from low-dose exposures to ionizing radiation: Results of parallel analysis of three exposed populations of women. *J Natl Cancer Inst.* 1980;65:353-76.
2. Kaplan HS, Hirsch BB, Brown MB. Indirect Induction of Lymphomas in Irradiated Mice: IV. Genetic Evidence of the Origin of the Tumor Cells from the Thymic Grafts. *Cancer Res.* 1956;16:434-6.
3. Barcellos-Hoff MH, Derynck R, Tsang ML-S, Weatherbee JA. Transforming growth factor- $\beta$  activation in irradiated murine mammary gland. *J Clin Invest.* 1994;93:892-9.
4. Amundson SA, Do KT, Fornace AJJ. Induction of stress genes by low doses of gamma rays. *Radiat Res.* 1999;152:225-31.
5. Mancuso M, Pasquali E, Leonardi S, Tanori M, Rebessi S, Di Majo V, et al. Oncogenic bystander radiation effects in Patched heterozygous mouse cerebellum. *Proc Natl Acad Sci (USA).* 2008;105:12445-50.
6. Blakely EA, Chang PY. Biology of Charged Particles. *The Cancer Journal.* 2009;15:271.
7. Durante M, Cucinotta FA. Heavy ion carcinogenesis and human space exploration. *Nat Rev Cancer.* 2008;8:465-72.
8. Loeffler JS, Durante M. Charged particle therapy--optimization, challenges and future directions. *Nat Rev Clin Oncol.* 2013;10:411-24.
9. Tubiana M, Aurengo A, Averbeck D, Bonnin A, Le Guen B, Masse R, et al. Dose-effect relationships and estimation of the carcinogenic effect of low doses of ionizing radiation. Paris: Académie des Sciences - Académie Nationale de Médecine 2005 March.
10. Barcellos-Hoff MH, Adams C, Balmain A, Costes SV, Demaria S, Illa-Bochaca I, et al. Systems biology perspectives on the carcinogenic potential of radiation. *Journal of Radiation Research.* 2014;55:i145-i54.
11. Barcellos-Hoff MH, Nguyen DH. Radiation carcinogenesis in context: How do irradiated tissues become tumors? *Health Physics.* 2009;97:446-57.

12. Nguyen DH, Bochaca II, Barcellos-Hoff MH. The biological impact of radiation exposure on breast cancer development. In: Russo J, editor. *Breast Cancer and the Environment*. New York: Springer 2010.
13. Mueller MM, Fusenig NE. Friends or foes--Bipolar effects of the tumor stroma in cancer. *Nat Rev Cancer*. 2004;4:839-49.
14. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. *Nat Med*. 2008;14:518-27.
15. Barcellos-Hoff MH, Lyden D, Wang TC. The evolution of the cancer niche during multistage carcinogenesis. *Nat Rev Cancer*. 2013;13:511-8.
16. Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. *Cancer Res*. 2000;60:1254-60.
17. Murphy KL, Rosen JM. Mutant p53 and genomic instability in a transgenic mouse model of breast cancer [see comments]. *Oncogene*. 2000;19:1045-51.
18. Kuperwasser C, Hurlbut GD, Kittrell FS, Dickinson ES, Laucirica R, Medina D, et al. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. *Am J Pathol*. 2000;157:2151-9.
19. Medina D, Kittrell FS, Shepard A, Stephens LC, Jiang C, Lu J, et al. Biological and genetic properties of the p53 null preneoplastic mammary epithelium. *Faseb J*. 2002;16:881-3.
20. Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, et al. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. *Oncogene*. 2000;19:1052-8.
21. Yan H, Blackburn AC, McLary SC, Tao L, Roberts AL, Xavier EA, et al. Pathways contributing to development of spontaneous mammary tumors in BALB/c-*Trp53*<sup>+/-</sup> mice. *Am J Pathol*. 2010;176.
22. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, et al. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. *Proceedings of the National Academy of Sciences*. 2011;109:2778-83.
23. Rajkumar L, Kittrell F, Guzman R, Brown P, Nandi S, Medina D. Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models. *Breast Cancer Research*. 2007;9:R12.

24. Dunphy K, Blackburn A, Yan H, O'Connell L, Jerry DJ. Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/- mice. *Breast Cancer Research*. 2008;10:R43.
25. Abba MC, Hu Y, Levy CC, Gaddis S, Kittrell FS, Hill J, et al. Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model. *Cancer Prev Res*. 2009;2:175-84.
26. Medina D, Kittrell F, Hill J, Zhang Y, Hilsenbeck SG, Bissonette R, et al. Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. *Cancer Prev Res*. 2009;2:168-74.
27. Mazumdar A, Medina D, Kittrell FS, Zhang Y, Hill JL, Edwards DE, et al. The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice. *Cancer Prev Res (Phila)*. 2012;5:1195-202.
28. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. *Cancer Res*. 2008;68:4674-82.
29. Vadakkan TJ, Landua JD, Bu W, Wei W, Li F, Wong ST, et al. Wnt-Responsive Cancer Stem Cells Are Located Close to Distorted Blood Vessels and Not in Hypoxic Regions in a p53-Null Mouse Model of Human Breast Cancer. *Stem cells translational medicine*. 2014.
30. Nguyen DH, Oketch-Rabah HA, Illa-Bochaca I, Geyer FC, Reis-Filho JS, Mao JH, et al. Radiation Acts on the Microenvironment to Affect Breast Carcinogenesis by Distinct Mechanisms that Decrease Cancer Latency and Affect Tumor Type. *Cancer Cell*. 2011;19:640-51.
31. Nguyen DH, Fredlund E, Zhao W, Perou CM, Balmain A, Mao J-H, et al. Murine Microenvironment Metaprofiles Associate with Human Cancer Etiology and Intrinsic Subtypes. *Clin Cancer Research*. 2013;19:1353-62.
32. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J Clin Oncol*. 1999;17:1474-81.
33. Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. *Bioinformatics*. 2010;26:2363-7.

34. Pavlidis P, Noble W. Analysis of strain and regional variation in gene expression in mouse brain. *Genome Biology*. 2001;2:research0042.1 - research.15.
35. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. *Pathology*. 2009;41:40-7.
36. Tang J, Fernandez-Garcia I, Vijayakumar S, Martinez-Ruiz H, Illa-Bochaca I, Nguyen DH, et al. Irradiation of juvenile, but not adult, mammary gland increases stem cell self-renewal and estrogen receptor negative tumors. *Stem Cells*. 2013;32:649-61.
37. Visvader JE. Cells of origin in cancer. *Nature*. 2011;469:314-22.
38. Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, et al. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. *The Journal of Clinical Investigation*. 2014;124:859-70.
39. Lim E, Wu D, Pal B, Bouras T, Asselin-Labat ML, Vaillant F, et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. *Breast Cancer Res*. 2010;12:R21.
40. Ringnér M, Fredlund E, Häkkinen J, Borg Å, Staaf J. GOBO: Gene Expression-Based Outcome for Breast Cancer Online. *PLoS ONE*. 2011;6:e17911.
41. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. *Cancer Res*. 2005;65:8530-7.
42. Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat M-L, Oakes SR, et al. Notch Signaling Regulates Mammary Stem Cell Function and Luminal Cell-Fate Commitment. *Cell Stem Cell*. 2008;3:429-41.
43. Costes S, Streuli CH, Barcellos-Hoff MH. Quantitative image analysis of laminin immunoreactivity in skin basement membrane irradiated with 1 GeV/nucleon iron particles. *Radiat Res*. 2000;154:389-97.
44. Lorimore SA, Coates PJ, Wright EG. Radiation-induced genomic instability and bystander effects: inter-related nontargeted effects of exposure to ionizing radiation. *Oncogene*. 2003;22:7058-69.
45. NAS/NRC. Health Risks from Exposure to Low Levels of Ionizing Radiation: Phase 2. Washington: National Academy Press; 2006.

46. Fornace AJJ, Amundson SA, Bittner M, Myers TG, Meltzer P, Weinstein JN, et al. The complexity of radiation stress responses: analysis by informatics and functional genomics approaches. *Gene Expression*. 1999;7:387-400.
47. Tsai KK, Chuang EY, Little JB, Yuan ZM. Cellular mechanisms for low-dose ionizing radiation-induced perturbation of the breast tissue microenvironment. *Cancer Res*. 2005;65:6734-44.
48. Andarawewa KL, Costes SV, Fernandez-Garcia I, Chou WS, Ravani SA, Park H, et al. Radiation Dose and Quality Dependence of Epithelial to Mesenchymal Transition (EMT) Mediated by Transforming Growth Factor  $\beta$ . *Int J Rad Onc Biol Phys*. 2011;79:1523-31.



## Figure Legends

**Figure 1: Host irradiation increases *Trp53* null tumor growth.** (A) Timeline of the host-irradiation experiment. (B) Median day to tumor detection as a function of host. (C-G). Growth rates of individual tumors in (C) sham-irradiated control mice (n=23), or (D)  $\gamma$  100 cGy (n=12), (E) Si 11 cGy (n=14), (F) Si 30 cGy (n=12), and (G) Si 81 cGy (n=9) irradiated hosts. (H) Tumor volume at day 30 generated from fitted tumor growth curves for each irradiation group and the calculated volume was averaged per treatment. Two-way ANOVA was performed to compare the tumor volume at each day between different irradiation groups. Sham: n=23;  $\gamma$  100 cGy: n=12; Si 11 cGy: n= 14; Si 30 cGy: n=12; Si 81 cGy: n=9. \*\*\*\*,  $p < 0.0001$ , compared to the sham-irradiated group. ##,  $p < 0.01$ , ####,  $p < 0.0001$ , compared to  $\gamma$  100 cGy or Si 11 cGy.

**Figure 2: Host irradiation affects the distribution of *Trp53* null mammary carcinomas.** (A-F) Dual immunostaining using keratin 14 and keratin 8/18 antibodies of (A) normal mammary duct. The basal, myoepithelial cell populations are stained positively for K14 (red) and the luminal, epithelial cells are positive for K18 (green). (B-F) Keratin patterns found in *Trp53* null mammary tumors (n=66) were characterized as (B) K18 type (n=22, yellow), (C) K14 (n= 5, blue), (D) K14/18 type with cells positive either for K18 or K14 (n=20, green), (E) K14+18 type with K14 and K18 co-localized in the same cells (n=8, orange), and (F) K18 and K14 negative type (n=11, black). (G-J) Frequency of different keratin tumor types in (G) all mice (n=66), (H) sham-irradiated hosts (n=21), (I)  $\gamma$ -irradiated hosts (Sparsely IR, n=10) and (J) Si-irradiated hosts (Densely IR, n=35). (K-N) The frequency of ER-negative tumor as a function of keratin tumor type from (K) all, or (L) sham-irradiated, (M)  $\gamma$ -irradiated and (N) Si-irradiated hosts as above. The number of tumor in each keratin tumor type was indicated on top of each bar.

**Figure 3. Host irradiation enhances tumor growth and lung metastasis in K18 but not K14/18 tumors.** (A-B) Tumor volumes at day 30 for (A) K18 and (B) K14/18 tumors from sham-,  $\gamma$ -, or Si-irradiated mice. Two-way ANOVA was performed to compare the tumor volume at each day between different irradiation groups. \*\*\*,  $p < 0.001$ , compared to the sham-irradiated group. (C-D) Observed frequency of lung metastasis from mice that previously developed a K18(C) or K14/18(D) mammary gland tumor. Only mice developed with unilateral mammary tumor were included.


**Figure 4. Association between tumor features and radiation dose and quality.** Multidimensional scaling analysis was used to investigate how different tumor phenotypes are associated with each other in different radiation treated group. (A) Tumor features were similarly associated among in tumors arising in mice irradiated with Si 11 cGy or  $\gamma$  100 cGy or sham-irradiated. (B) A similar pattern of association was evident among tumor features in Si 30 cGy and Si 81 cGy treated groups. (C) Discriminant analysis was used to find whether these phenotypes can distinguish one radiation treated group from others. The group centroid, which averages the functional values, shows that tumor phenotypes discriminate between tumors arising in irradiated mice.

**Figure 5. Comparison of features of K18 vs K14/18 tumors.** (A) Heatmap of K18 vs K14/18 profile. Differentially expressed genes between K18 and K14/18 were identified by PTM. Important genes, biological process and pathway were marked on the heatmap. Genes in bold were keratins differentially expressed between K18 and K14/18 tumors. (B) Unsupervised clustering of 1,608 human breast cancers using 573 human orthologs of the murine genes from the K18 vs K14/18 profile. Tumors were segregated into 4 subgroups, some of which contained a predominant molecular subtype (luminal A, light blue; luminal B, dark blue; ERBB2, yellow; basal-like, red; normal-like, grey; and unclassified, black). (C-D) Gene expression profile from ER-neg tumors (ER-neg-IHPsi) and ER-pos tumors (ER-pos-IHPsi) arising from Si-irradiated host were identified using PTM ( $p < 0.05$ ,  $FC > 1.25$ ). 1078 genes( 669 were upregulated and 409 were downregulated) were differentially expressed in ER(-) tumors upon host irradiation. 77 genes were upregulated while 73 were downregulated in ER(+) tumors after host irradiation.


**Figure 6. Host irradiation promotes distinct expression profiles in K18 and K14/18 tumors.** (A) Canonical pathways identified by IPA. The  $p$ -value  $\leq 0.01$  or  $-\log_{10}(p\text{-value}) \geq 2$  suggest that there is a significant overlap between a set of genes in K18 IHPsi (black bar) or K14/18-IHPsi(open bar) and genes implicated in a particular pathway. (B) Upstream regulators identified by IPA. The upstream regulators that are expected to be increased or decreased according to the gene expression changes in K18-IHPsi (black bar) or K14/18-IHPsi (open bar) were identified using the IPA z-score algorithm. A positive or negative z-score value indicates that upstream regulator is predicted to be

activated or inhibited by host irradiation in specific tumor type. Only upstream regulators with a z-score  $\geq 2$  or  $\leq -2$  were considered as significant.


**Figure 1**




**Figure 2**




**Figure 3**



**Figure 4**




**Figure 5**





**Figure 6**



# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Densely Ionizing Radiation Acts via the Microenvironment to Promote Aggressive Trp53 Null Mammary Carcinomas

Irineu Illa-Bochaca, Haoxu Ouyang, Jonathan Tang, et al.

*Cancer Res* Published OnlineFirst October 10, 2014.

<b>Updated version</b>	Access the most recent version of this article at: doi: <a href="https://doi.org/10.1158/0008-5472.CAN-14-1212">10.1158/0008-5472.CAN-14-1212</a>
<b>Supplementary Material</b>	Access the most recent supplemental material at: <a href="http://cancerres.aacrjournals.org/content/suppl/2014/10/11/0008-5472.CAN-14-1212.DC1">http://cancerres.aacrjournals.org/content/suppl/2014/10/11/0008-5472.CAN-14-1212.DC1</a>
<b>Author Manuscript</b>	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://cancerres.aacrjournals.org/content/early/2014/10/10/0008-5472.CAN-14-1212>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.